SEC Comment Letter for MetaVia Inc. (MTVA) (CIK 0001638287) (MTVA) — Sep 7, 2017
MetaVia Inc. (MTVA) (CIK 0001638287)
Date: Sept. 7, 2017 · CIK: 0001638287 · Accession: 0000000000-17-031606
AI Filing Summary & Sentiment
Reasoning
Letter
September 7, 2017 Steven Gullans Interim President and Chief Executive Officer Gemphire Therapeutics Inc. 17199 N. Laurel Park Drive, Suite 401 Livonia, Michigan 48152 Gemphire Therapeutics Inc. Registration Statement on Form S-3 Filed September 1, 2017 File No. 333-220315Re: Dear Dr. Gullans: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at (202) 551-6553 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Meredith Ervine, Esq. - Honigman Miller Schwartz and Cohn LLP
Show Raw Text
September 7, 2017 Steven Gullans Interim President and Chief Executive Officer Gemphire Therapeutics Inc. 17199 N. Laurel Park Drive, Suite 401 Livonia, Michigan 48152 Gemphire Therapeutics Inc. Registration Statement on Form S-3 Filed September 1, 2017 File No. 333-220315Re: Dear Dr. Gullans: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at (202) 551-6553 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Meredith Ervine, Esq. - Honigman Miller Schwartz and Cohn LLP